Evidence map›Paper›PMID 39034827›Full record

ArticleGlobal health action2024

Kathiresan Jeyashree, Jeromie W V Thangaraj, Devika Shanmugasundaram, G Sri Lakshmi Priya, Sumit Pandey, Venkateshprabhu Janagaraj, Prema Shanmugasundaram, Sumitha Ts, Sabarinathan Ramasamy, Joshua Chadwick and 9 more

Erratum issuedAbstract read
In one paragraph

Article in Global health action, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Kathiresan JeyashreeDivision of Epidemiology and Biostatistics, ICMR-National Institute of Epidemiology, Chennai, India.ORCID 0000-0001-6459-3659
Jeromie W V ThangarajDivision of Epidemiology and Biostatistics, ICMR-National Institute of Epidemiology, Chennai, India.
Devika ShanmugasundaramDivision of Epidemiology and Biostatistics, ICMR-National Institute of Epidemiology, Chennai, India.
G Sri Lakshmi PriyaDivision of Epidemiology and Biostatistics, ICMR-National Institute of Epidemiology, Chennai, India.
Sumit PandeyDivision of Epidemiology and Biostatistics, ICMR-National Institute of Epidemiology, Chennai, India.
Venkateshprabhu JanagarajDivision of Epidemiology and Biostatistics, ICMR-National Institute of Epidemiology, Chennai, India.
Prema ShanmugasundaramDivision of Epidemiology and Biostatistics, ICMR-National Institute of Epidemiology, Chennai, India.
Sumitha TsDivision of Epidemiology and Biostatistics, ICMR-National Institute of Epidemiology, Chennai, India.
Sabarinathan RamasamyDivision of Epidemiology and Biostatistics, ICMR-National Institute of Epidemiology, Chennai, India.
Joshua ChadwickDivision of Epidemiology and Biostatistics, ICMR-National Institute of Epidemiology, Chennai, India.
Sivavallinathan ArunachalamTB Support Network, WHO Country Office for India, New Delhi, India.
Rahul SharmaTB Support Network, WHO Country Office for India, New Delhi, India.
Vaibhav ShahTB Support Network, WHO Country Office for India, New Delhi, India.
Aniket ChowdhuryTB Support Network, WHO Country Office for India, New Delhi, India.
Swati IyerTB Support Network, WHO Country Office for India, New Delhi, India.
Raghuram RaoCentral TB Division, Ministry of Health and Family Welfare, New Delhi, India.
Sanjay K MattooCentral TB Division, Ministry of Health and Family Welfare, New Delhi, India.
Manoj V MurhekarDivision of Epidemiology and Biostatistics, ICMR-National Institute of Epidemiology, Chennai, India.
Npy Evaluation Group

Funding

World Health Organization 001
6 · The paper itself

Abstract

background

objectivesTo determine the proportion of PwTB receiving atleast one NPY instalment and pattern of utilisation; to ascertain factors associated with NPY non-receipt and association of NPY receipt with TB treatment outcome.

methodsIn our cross-sectional study, we used multi-stage sampling to select PwTB whose treatment outcome was declared between May 2022 and February 2023. A cluster-adjusted, generalized linear model was used to identify factors associated with the non-receipt of NPY and determine association between NPY receipt and TB treatment outcome.

resultsAmong 3201 PwTB, 2888 (92.7%; 95% CI 89.8%, 94.8%) had received at least one NPY instalment, and 1903 (64.2%; 95% CI 58.9%, 69.2%) self-reported receipt of benefit. The median (IQR) time to receipt of first instalment was 105 (60,174) days. Non-receipt was significantly higher among PwTB from states with low TB score (aPR = 2.34; 95%CI 1.51, 3.62), who do not have bank account (aPR = 2.48; 95%CI 1.93, 3.19) and with unknown/missing diabetic status (aPR = 1.69; 95%CI 1.11, 2.55). Unfavorable treatment outcomes were associated with non-receipt of NPY (aPR 4.93; 95%CI 3.61,6.75) after adjusting for potential confounders.

conclusionMajority of the PwTB received atleast one NPY instalment, but they experience significant delays. Most of the recipients utilised NPY for nutrition. Longitudinal follow-up studies are required to study the impact of NPY on treatment outcomes.

Indexed as

TuberculosisAdolescentAdultAntitubercular AgentsCross-Sectional StudiesFemaleHumansIndiaMaleMiddle AgedNational Health ProgramsTreatment OutcomeYoung AdultAntitubercular AgentsdelayDirect benefit transfernutritionpattern of utilizationtreatment outcome

Identifiers

PMID39034827
PMCPMC11265306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.